Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

ProQR Therapeutics N.V (PRQR) Shares Outstanding (Diluted Average): 2021-2025

Historic Shares Outstanding (Diluted Average) for ProQR Therapeutics N.V (PRQR) over the last 4 years, with Sep 2025 value amounting to $123.2 million.

  • ProQR Therapeutics N.V's Shares Outstanding (Diluted Average) rose 37.29% to $123.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $123.2 million, marking a year-over-year increase of 37.29%. This contributed to the annual value of $92.0 million for FY2024, which is 4.98% up from last year.
  • Per ProQR Therapeutics N.V's latest filing, its Shares Outstanding (Diluted Average) stood at $123.2 million for Q3 2025, which was up 33.88% from $92.0 million recorded in Q4 2024.
  • ProQR Therapeutics N.V's 5-year Shares Outstanding (Diluted Average) high stood at $123.2 million for Q3 2025, and its period low was $61.3 million during Q1 2021.
  • Its 3-year average for Shares Outstanding (Diluted Average) is $92.4 million, with a median of $88.2 million in 2023.
  • Its Shares Outstanding (Diluted Average) has fluctuated over the past 5 years, first fell by 10.59% in 2022, then skyrocketed by 37.29% in 2025.
  • Quarterly analysis of 5 years shows ProQR Therapeutics N.V's Shares Outstanding (Diluted Average) stood at $80.5 million in 2021, then declined by 10.59% to $73.1 million in 2022, then increased by 19.25% to $87.2 million in 2023, then rose by 5.54% to $92.0 million in 2024, then spiked by 37.29% to $123.2 million in 2025.
  • Its last three reported values are $123.2 million in Q3 2025, $92.0 million for Q4 2024, and $89.7 million during Q3 2024.